为您找到"
boin
"相关结果约100,000,000个
Simulate 3+3 design for comparison: Match maximum sample size between BOIN and 3+3 Perform cohort expansion on 3+3 to match the sample size of BOIN Match the sample size of BOIN to that of 3+3 Enter Simulation Scenarios Add a Scenario Remove a Scenario Save Scenarios Set Seed: For each scenario, enter true toxicity rate of each dose level: Run ...
The TITE-BOIN-ET (Time-to-Event-BOIN Efficacy Toxicity) design is an extension of the BOIN-ET design that has been proposed to consider the following factors in dose finding: 1) fast accrual rates, 2) the difference in evaluation periods for toxicity and efficacy, and 3) the late onset outcomes [37].
BOIN is a novel model-assisted phase-1 trial design that is easy to implement and superior to other designs. Find MTD for single-agent, drug combination, or platform trials with BOIN software tools and publications.
BOIN (Bayesian Optimal Interval Design) is a model-assisted design that uses the observed dose-limiting toxicity rate to guide dose escalation and de-escalation. Learn how BOIN can improve the accuracy, safety and reliability of phase I trials for single-agent and drug-combination therapies.
BOIN is a Bayesian optimal interval design that balances simplicity and performance in finding the maximum tolerated dose (MTD) for single-agent or drug-combination trials. It is a simple algorithm-based method that reduces the risk of subtherapeutic or overly toxic doses.
Learn how to use the Bayesian optimal interval (BOIN) design, a novel and easy-to-implement phase I trial design for finding the maximum tolerated dose (MTD). The tutorial covers the trial design, dose assignment, and operating characteristics using the R package BOIN.
The TITE-BOIN-ET (Time-to-Event-BOIN Efficacy Toxicity) design is an extension of the BOIN-ET design that has been proposed to consider the following factors in dose finding: 1) fast accrual rates, 2) the difference in evaluation periods for toxicity and efficacy, and 3) the late onset outcomes [37].
The BOIN design contains the 3 + 3 design and the accelerated titration design as special cases, thus linking it to established phase I approaches. A numerical study shows that the BOIN design generally outperforms the 3 + 3 design and the modified toxicity probability interval (mTPI) design.
BOIN is a novel phase I clinical trial design for finding the maximum tolerated dose (MTD) of a new drug. It achieves simplicity and superior performance by minimizing the risk of subtherapeutic or overly toxic doses.
BOIN is a Bayesian optimal interval design that balances simplicity and performance for finding the maximum tolerated dose (MTD) of a new drug. It can be used for single-agent or drug-combination trials and has a lower risk of subtherapeutic or overly toxic doses.